Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

CD105 (Endoglin) as negative prognostic factor in AML.

Joseph Kauer1,2, Karolin Schwartz1,2, Claudia Tandler3,4

  • 1Institute for Cell Biology, Department of Immunology, University of Tübingen, Tübingen, Germany.

Scientific Reports
|December 5, 2019
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Feasibility and safety of rapid glofitamab ramp-up.

Leukemia·2026
Same author

B7-H3 membranous expression correlates with histological grading in a two-center cohort of 133 pre-treatment bone and soft tissue sarcoma samples.

BMC cancer·2026
Same author

B7-H3 (CD276) as Target for T Cell-Based Bispecific Antibody Therapy of Penile Cancer.

ImmunoTargets and therapy·2026
Same author

Senescence in cancer: Hallmarks, paradoxes, and therapeutic promise.

Cell·2026
Same author

A convergent uPAR-positive tumor ecosystem creates broad vulnerability to CAR T cell therapy.

Cell·2026
Same author

Characterization of TROP-2 bispecific T cell engagers for immunotherapy of triple negative breast and bladder cancer.

Frontiers in immunology·2026
This summary is machine-generated.

High CD105 expression is a new prognostic marker for acute myeloid leukemia (AML). This finding may help optimize treatment and follow-up for AML patients, improving survival outcomes.

Area of Science:

  • Hematology
  • Oncology
  • Immunology

Background:

  • Established genetic and morphological markers aid acute myeloid leukemia (AML) therapy, yet better patient stratification is needed.
  • CD105 (Endoglin), a transmembrane protein, is implicated in endothelial cell activation and proliferation, and expressed in hematological malignancies and tumor vasculature.
  • While CD105 is linked to unfavorable disease courses in solid tumors, its prognostic relevance in hematological malignancies remains unexplored.

Purpose of the Study:

  • To investigate the expression and prognostic significance of CD105 in a cohort of acute myeloid leukemia (AML) patients.
  • To determine if CD105 surface expression levels can serve as a predictive biomarker for AML patient outcomes.

Main Methods:

  • Development of a novel CD105 antibody for expression analysis.

Related Experiment Videos

  • Flow cytometry was used to quantify CD105 surface expression across different AML subtypes (FAB classification).
  • Receiver-operating characteristic (ROC) analysis established a cutoff (5.22) to categorize patients into CD105-low and CD105-high groups.

    • Main Results:

    • Substantial CD105 expression was observed in various AML FAB types, with significantly lower levels in FAB M3.
    • A CD105 expression cutoff of 5.22 distinguished between CD105-low and CD105-high patient groups.
    • High CD105 surface expression significantly correlated with poorer overall survival and progression-free survival.

    Conclusions:

    • CD105 expression is identified as a novel prognostic marker in acute myeloid leukemia (AML).
    • CD105 levels can potentially stratify AML patients, aiding in treatment decisions and follow-up strategies.
    • This finding offers a new avenue for improving risk assessment and therapeutic management in AML.